Information icon.svg At All things in moderation, we are currently voting on restrictions on the use of LLMs (chatbots) in RationalWiki. Reminder: you need to have at least 75 edits and to have been registered for at least three months to be eligible to vote.


From RationalWiki
Jump to navigation Jump to search
Against allopathy
Alternative medicine
Clinically unproven

Poly-MVA (or Polydox) is a dietary supplement created by Merrill Garnett (b. 1931), a former dentist turned biochemist. Poly-MVA is an ineffective alternative cancer treatment.[1]


The "MVA" in "Poly-MVA" means "minerals vitamins and amino acids".[1] Poly-MVA contains lipoic acid, acetylcysteine, palladium, B vitamins, and other ingredients.[2] The substance is red-brown liquid that is taken by mouth.[1] Promoters of Poly-MVA refer to it as a "metallo-vitamin".[1]

In 2004, a year's supply of Poly-MVA was reported as costing US$19,800.[3]

Alternative medicine[edit]

Poly-MVA is promoted with claims that it can treat a variety of human diseases including cancer and HIV/AIDS.[1] The promotional effort is supported by customer testimonials, but there is no medical evidence that Poly-MVA confers any health benefit and some concern it may inhibit the effectiveness of mainstream cancer treatments if used at the same time.[1][2]

In 2005, Poly-MVA was listed as one of the ineffective alternative cancer treatments being sold by the clinics clustered in and around Tijuana, Mexico.[4]

External links[edit]

See also[edit]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 Russell J, Rovere A, ed (2009). "Poly-MVA". American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies (2nd ed.). American Cancer Society. pp. 804-807. ISBN 9780944235713. 
  2. 2.0 2.1 "Polydox". Herb-drug Interactions in Oncology. PMPH-USA. 2010. p. 536. ISBN 978-1-60795-041-7. 
  3. "Is this cancer-fighting supplement too good to be true?". Women's Health Letter (May): 4. 2004. 
  4. Moss, R. W. (2005). "Patient Perspectives: Tijuana Cancer Clinics in the Post-NAFTA Era". Integrative Cancer Therapies 4 (1): 65–86. PMID 15695477.